GlassScriptPhysician profile
Kevin M Comar
NPI 1184832909
$9,421.04
in general payments reported to CMS, 2019-2025
35 companies · $1,623 in 2025
The $1,623 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,051 · 2020: $300 · 2021: $1,071 · 2022: $1,602 · 2023: $2,118 · 2024: $1,655 · 2025: $1,623.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,397.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,396.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,212.60 | 2019-2025 | Skyrizi, Rinvoq, Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $969.83 | 2019-2025 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $646.66 | 2019-2025 | Stelara, Tremfya, Simponi |
| Celgene Corporation | $557.00 | 2021-2024 | Zeposia |
| Genzyme Corporation | $418.82 | 2022-2025 | |
| Lilly USA, LLC | $383.62 | 2023-2025 | Omvoh, Zepbound |
| Takeda Pharmaceuticals U.S.A., INC. | $365.35 | 2019-2025 | Entyvio, Gattex |
| Regeneron Healthcare Solutions, INC. | $332.12 | 2023-2025 | Dupixent |
| Merck Sharp & Dohme LLC | $299.71 | 2019-2024 | Dificid |
| Qol Medical, LLC | $285.02 | 2021-2025 | Sucraid, Sucraid |
| Pfizer INC. | $283.70 | 2023-2025 | |
| Gilead Sciences, INC. | $244.37 | 2019-2025 | |
| Madrigal Pharmaceuticals | $157.79 | 2025 | Rezdiffra |
| Ironwood Pharmaceuticals, INC | $151.33 | 2021-2024 | Linzess |
| Olympus America INC. | $149.11 | 2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $138.83 | 2021 | |
| Nestle Healthcare Nutrition INC. | $86.93 | 2021-2022 | |
| Redhill Biopharma INC. | $86.32 | 2020-2022 | |
| Intercept Pharmaceuticals, INC. | $85.45 | 2019-2025 | |
| Allergan, INC. | $82.36 | 2019-2020 | |
| Vivus LLC | $72.27 | 2021-2024 | Qsymia |
| Daiichi Sankyo INC. | $61.65 | 2019 | |
| Ucb, INC. | $59.30 | 2019 | |
| Aimmune Therapeutics, INC. | $51.22 | 2024-2025 | Zenpep |
| Shire North American Group INC | $42.23 | 2019 | |
| Shionogi INC | $40.03 | 2019 | |
| Ferring Pharmaceuticals INC. | $36.90 | 2025 | Rebyota |
| Novo Nordisk INC | $26.93 | 2025 | Wegovy |
| Phathom Pharmaceuticals, INC. | $24.86 | 2025 | Voquezna |
| Ardelyx, INC. | $23.63 | 2023 | Ibsrela |
| Ipsen Biopharmaceuticals, INC | $16.05 | 2025 | Iqirvo |
| Boston Scientific Corporation | $15.80 | 2021 | |
| Lexicon Pharmaceuticals, INC. | $13.25 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Comar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.